#ASCO21: Novartis keeps building out survival data for Kisqali, hoping to keep the pressure on Pfizer's Ibrance

As Novartis’ Kisqali for breast cancer trails Pfizer’s Ibrance in sales, the Swiss biopharma continues to trot out long-term survival data it hopes will flesh out the drug’s overall profile.

Ahead of #ASCO21 this weekend, Novartis teased out more data for the CDK4/6 inhibitor for postmenopausal HR-positive, HER2-negative metastatic breast cancer patients. With more than four years of follow-up, Kisqali in combination with AstraZeneca’s Faslodex provided more than a year of extra survival benefit compared to Faslodex alone.